Prognostic significance of receptor for advanced glycation end products expression in XXXX after hepatectomy.

@entity1 @entity66 @entity5 @entity157 @entity4283 @entity1349
BACKGROUND: The receptor for advanced glycation end products ( @entity4283 ) is recognized to be responsible for @entity5 progression in several @entity1 @entity5 . In this study, we investigated the clinical impact of @entity4283 expression in @entity1 with @entity157 ( @entity157 ) after hepatectomy. MATERIALS AND METHODS: Sixty-five consecutive @entity1 who underwent initial hepatectomy for @entity157 were investigated. The relationships between immunohistochemical expression of @entity4283 and clinicopathologic features, clinical outcome ( @entity1349 [ @entity1349 ], and @entity66 [ @entity66 ]) were evaluated. RESULTS: The cytoplasmic expression of @entity4283 in @entity157 cells was observed in 46 @entity1 (70.8%) and correlated with histologic grade (poorly differentiated versus moderately differentiated @entity157 , P  =  0.021). Five-year @entity1349 in @entity4283 -positive and @entity4283 -negative groups were 72% and 94%, respectively, whereas 5-y @entity66 were 29% and 55%, respectively. There were significant differences between @entity1349 and @entity66 (P  =  0.018 and 0.031, respectively). Multivariate analysis indicated that @entity4283 was an independent predictor for both @entity1349 and @entity66 (P  =  0.048 and 0.032, respectively). CONCLUSIONS: Our data suggest for the first time a positive correlation between @entity4283 expression and poor therapeutic outcome. Furthermore, @entity4283 downregulation may provide a novel therapeutic target for @entity157 .
